舒血宁联合依达拉奉治疗急性脑梗死

Clinical Effect of Shuxuening Combined with Edaravone for Acute Cerebral Infarction

目的:探讨舒血宁联合依达拉奉治疗急性脑梗死的临床疗效。方法:将120例急性脑梗死患者随机分为联合组60例及对照组60例,联合组予舒血宁联合依达拉奉治疗,对照组予依达拉奉治疗。观察治疗2周后神经功能缺损评分(NDS)的变化,并比较其临床疗效。结果:治疗前后NDS评分,联合组为(22.5±4.15),(16.71±4.82)分;对照组为(23.1±3.99),(19.12±3.94)分,联合组改善优于对照组(P<0.05)。联合组治疗总有效率为88.3%,对照组为73.3%,两组临床疗效相比差异有统计学意义(P<0.05)。结论:舒血宁与依达拉奉联合治疗急性脑梗死患者疗效确切,有利于减轻神经损伤程度,未见明显副作用。

Objective ： To investigate the clinical treatment for acute cerebral infarction. Method： One hundred were randomly divided into the combined treatment gl：oup and effects of Shuxuening combined with edaravone and tweenty patients with acute cerebral infarction control group （n = 60 each）. The patients in thecombined group were given Shuxuening with edaravone, the patients in the control group were given edaravone. The changes in neurological deficit scores （NDS） were investigated after two weeks of treatment, and the clinical efficacy was compared. Result： Before and after treatment, NDS scores were （22.5 ± 4. 15） and （16.71 ± 4. 82） in the combination group, while they were （23.1 ±3.99） and （19.12±3.94） in the control group. The difference after the treatment between the two groups was statistically significant （P 〈 0.05 ）. The clinical efficacy was 88.3% in combined treatment group, 73.3% in the control group, the difference was significant （P 〈 0.05）. Conclusion： Shuxuening combined with edaravone therapy for patients with acute cerebral infarction is effective. The therapy may reduce the extent of nerve damage without significant side effects.